Navigation Links
Amerigen Pharmaceuticals and the Shanghai Fosun Omni Pharmaceutical Company Enter Into Collaboration Agreement for the Development of Generic Oral Controlled Release Products
Date:1/11/2012

EAST BRUNSWICK, N.J. and SHANGHAI, Jan. 11, 2012 /PRNewswire/ -- Amerigen Pharmaceuticals Limited ("Amerigen") and the Shanghai Fosun Omni Pharmaceutical Co., Ltd ("Fosun Omni") today announced they had entered into a collaboration agreement regarding the development of generic oral controlled release products. Under the terms of the agreement, Fosun Omni will use its formulation expertise to develop products for Amerigen to commercialize in the United States and other territories. On signing the agreement, Fosun Omni received an up-front fee with respect to the first product and is eligible for additional product-specific development milestones and royalties on any commercialized products.

"This collaboration allows Amerigen to add further momentum to its efforts to build a portfolio of differentiated, high value generic pharmaceuticals," said Jonathan Embleton, Chief Business Officer for Amerigen. "Omni's internationally experienced scientific team will develop complex oral controlled release formulations for scale-up and commercial manufacture at Amerigen's FDA approved facility in Suzhou, which is only a two hour drive from Fosun Omni's operating base in Shanghai's Zhangjiang Hi-Tech Park.

CSO of the Fosun Omni, Dr Ping He, commented, "This collaboration with Amerigen continues Fosun Pharma's strategy to develop some difficult ANDA products to FDA and to speed up the product commercialization process for our partners. This is the first step of the collaboration."

About Amerigen
Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in East Brunswick, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Limited, is located in Suzhou, Jiangsu Province. The group has an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese SFDA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.

About Fosun Omni
Shanghai Fosun Omni Pharmaceutical Co., Ltd is a global pharmaceutical company devoted to development, out-licensing, formulation CRO services, and independent R&D for NDA and ANDA projects.  The company focuses are those difficult to develop, manufacture, and replicate oral solid formulations for regulated market and China market at highly competitive prices.


'/>"/>
SOURCE Amerigen Pharmaceuticals Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amerigen Pharmaceuticals and Stason Pharmaceuticals Enter Into Collaboration Agreement for Development of Generic Oral Oncology Products
2. Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products
3. E7: The Outlook for Pharmaceuticals to 2012
4. Oramed Pharmaceuticals Files US Patent Application for Combination Oral Treatment of Diabetes
5. The Outlook for Pharmaceuticals Worldwide
6. Omthera Pharmaceuticals Announces Positive Long Term Bioavailability Data Comparing Epanova™ to Lovaza®
7. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
8. KalVista Pharmaceuticals and JDRF Form Research Partnership Focused on Novel Approach for Treating Diabetic Eye Disease
9. Questcor Pharmaceuticals Reports Strong Finish to 2011
10. Valeant Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
11. Radient Pharmaceuticals Announces New Advertisement for Oncology Publications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Consumers have taken ... regulators/payers have placed more emphasis on patient outcomes. ... support programs in the pharmaceutical industry have evolved ... Consequently, pharmaceutical companies are focusing on becoming more ... providing products and services that improve health. ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
Breaking Medicine Technology:
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):